SLG
SRPT icon

Stanley-Laman Group’s Sarepta Therapeutics SRPT Stock Holding History

Stanley-Laman Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,168
Closed -$329K – 279
2019
Q2 		$329K Hold
2,168
– – 0.08% 219
2019
Q1 		$258K Buy
2,168
+50
+2% +$6.43K 0.06% 234
2018
Q4 		$231K Buy
+2,118
New +$265K 0.06% 235

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Stanley-Laman Group's SRPT Position: Q3 2019 in Review

Stanley-Laman Group sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 2,168 shares — an estimated $329K sold.

Stanley-Laman Group first reported a position in SRPT in Q4 2018 and held it in 3 quarters. The position peaked at $329K in Q2 2019. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Stanley-Laman Group reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Stanley-Laman Group sold 2,168 Sarepta Therapeutics shares in Q3 2019, an estimated $329K.
  • Stanley-Laman Group first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 3 quarters.
  • Stanley-Laman Group's Sarepta Therapeutics position peaked at $329K in Q2 2019.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Stanley-Laman Group's 13F filing for Q3 2019, filed 8 Nov 2019.